Skip to main content
. 2020 Oct 9;11:575390. doi: 10.3389/fphar.2020.575390

Figure 6.

Figure 6

Metformin (MET) restores the gestational diabetes mellitus (GDM)-induced angiogenesis impairment via downregulation of p65 and upregulation of Nrf2. (A) Nrf2 expression level in HUVECs treated with 0.5 μM Bay11-7082 (Bay) or 100 μM MET determined using Western blot. The Nrf2 level was quantified and shown on the right. (B) Western blot analysis of the p65 expression level in HUVECs treated with 5.5 or 35 mM D-Glucose with or without 100 μM MET. The p65 level was quantified and shown on the right. (C) Western blot analysis of nuclear and cytoplasmic p65 level in HUVECs treated with 5.5 or 35 mM D-Glucose with or without MET. Preparation of nuclear and cytoplasmic lysates and western blot were performed as described in the Methods section. The p65 level was quantified and shown on the right. All data are presented as mean ± SEM of 5 replicates, *P < 0.05 compared with normal group; #P < 0.05, ##P < 0.01, and ###P < 0.001 compared with 35 mM D-Glucose treatment group.